Clinical Trial Update: Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating prophylactic dosing of low molecular weight heparin in Child-Pugh B cirrhosis patients has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cirrhosis | Phase 3 | Status: SUSPENDED